Prime Medicine, Inc. — Form 10-Q Summary
Reporting period: Three and nine months ended September 30, 2022. Financial statements are unaudited. Prime Medicine is a preclinical biotechnology company developing Prime Editing gene-editing therapies; it reported no product revenue and had not initiated clinical development of a product candidate.
Financial position and results
| Metric | Q3 2022 / September 30, 2022 | Comparable period / prior year-end |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $25.0 million for Q3; $57.7 million for nine months | $7.4 million for Q3 2021; $17.7 million for nine months 2021 |
| General and administrative expense | $6.6 million for Q3; $20.2 million for nine months | $3.0 million for Q3 2021; $6.7 million for nine months 2021 |
| Net loss | $29.4 million for Q3; $82.5 million for nine months | $16.4 million for Q3 2021; $102.5 million for nine months 2021 |
| Net loss per common share | $1.61 for Q3; $4.91 for nine months | $1.52 for Q3 2021; $9.74 for nine months 2021 |
| Cash, cash equivalents and short-term investments | $146.7 million, excluding restricted cash | $269.6 million at December 31, 2021 |
| Current assets / current liabilities | $148.8 million / $22.2 million | — |
| Total liabilities / debt | $42.6 million; no debt outstanding | — |
| Operating cash flow | $(101.1) million for nine months | $(20.9) million for nine months 2021 |
No meaningful operating margin is reported because the company had no product revenue. The filing reports no debt outstanding; liabilities include operating lease obligations. The cash-flow statement reports $61.4 million of cash, cash equivalents and restricted cash at September 30, including $13.5 million of restricted cash.
Changes versus the prior comparable period
- Q3 net loss widened by $12.9 million year over year as operating expenses rose; R&D expense increased $17.6 million, driven mainly by lab supplies, hiring and expanded facilities.
- Nine-month net loss narrowed by $19.9 million, despite operating expenses increasing $53.5 million. The comparison benefited from 2021 non-cash fair-value losses on preferred-stock tranche rights and an anti-dilution obligation, which had been settled in 2021.
- Nine-month operating cash use rose to $101.1 million from $20.9 million. The company attributed the change in part to a $30.0 million payment to Myeloid in January 2022 and increased operating activity.
- Cash and investments declined from $269.6 million at year-end 2021 to $146.7 million at September 30, 2022, excluding restricted cash. In October, after the quarter, the IPO generated $180.3 million in net proceeds and all preferred stock converted into common stock.
Outlook, risks and unusual items
- Management expects operating losses and negative operating cash flows for the foreseeable future and expects expenses, particularly R&D, to rise as programs advance. It expects no product-sales revenue for several years, if ever.
- After including IPO proceeds, management estimates existing cash, cash equivalents and short-term investments will fund operating expenses and capital requirements into 2025. The estimate depends on assumptions that may change; additional financing will be required to support the strategy.
- The company completed its October 2022 IPO at $17.00 per share, issuing 11,721,456 shares and receiving $180.3 million net. The IPO also triggered conversion of preferred stock and certain performance-based equity awards.
- A planned Cambridge office and laboratory lease had not commenced by September 30. The company expects approximately $208.7 million of payments over its ten-year term; the obligation is excluded from reported lease liabilities and the disclosed lease-payment schedule at quarter-end.
- Other commitments include a pledge of $5.0 million annually to Broad Institute and Harvard for 14 years, beginning in 2021; the pledge may be terminated with one year of funding after notice. R&D expense associated with the pledge was $3.8 million for the first nine months of 2022.
- Prime Editing is novel and unvalidated in human therapeutics. Key risks include preclinical and clinical failure, delivery and safety uncertainties, regulatory uncertainty, competition, dependence on third parties and collaborators, and significant intellectual-property and licensing risks.
- A material weakness in internal control over financial reporting, related to segregation of duties, remained unremediated. Management concluded disclosure controls were ineffective as of September 30, 2022. The filing says the weakness had not caused a financial-statement misstatement.
- The company reported no material legal proceedings. COVID-19 disruptions, inflation, rising labor and R&D costs, and market volatility were identified as potential risks.
Important facts for investors to verify
- Whether preclinical programs meet stated milestones and progress toward IND submissions, and whether management’s into-2025 runway estimate remains supported by actual spending.
- The expected timing and financial impact of the $208.7 million uncommenced lease, alongside other lease and license commitments.
- Progress remediating the financial-reporting control weakness and any subsequent changes in control effectiveness.
- Whether Prime Editing’s efficacy, delivery, safety and intellectual-property position can be demonstrated; the filing reports no clinical validation.
- Post-IPO capitalization, dilution from equity awards and future financing needs, and any changes in the company’s use of IPO proceeds.